The Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) Survey:
Largest multinational survey to date providing true reflection of the profound impact of psoriasis and psoriatic arthritis (PsA) on patients and the community, as well as identifying several unmet needs

Population based survey of 3,426 patients and 781 physicians in North America (USA and Canada) and Europe (France, Germany, Italy, Spain and the UK)

Psoriasis and PsA have a profound effect on functional status and QoL; the greater the severity of the disease, the greater the impairment
- The impact of psoriasis and PsA on everyday activities is significant, with PsA patients with moderate severity of disease reporting “much difficulty” in performing a range of simple everyday tasks, such as bending down to pick up clothing

27% of psoriasis patients and 53% of PsA patients rated their disease as severe
- Patients frequently reported greater severity of disease than assessed by their HCP, suggesting that guidelines for rating disease severity need to be reassessed

The majority of patients were either undertreated or not being treated systematically, despite the significant impact of psoriasis and PsA
- 50% of psoriasis patients had not seen a health care professional in the past 12 months, and 63% of PsA patients were not being treated for their joint disease

85% of patients reported that there is a need for better therapies
- Many patients discontinued oral and biologic therapies due to safety and tolerability concerns or because of a lack or loss of effectiveness